Zynerba Pharmaceuticals Inc ZYNE announced Thursday its Phase 2 trial for ZYN002 in Fragile X syndrome found sustained improvements in patients’ core behavioral symptoms.
The drug was well tolerated with no serious adverse events.
Why It’s Important
The candidate is the most advanced in Zynerba’s pipeline, and its progress promises near-term revenue opportunity.
"These data are consistent and compelling, and suggest that ZYN002 may have a clinically meaningful and durable effect on the most common observable behaviors associated with childhood and adolescent Fragile X syndrome," Honey Heussler, lead investigator in the study, said in a press release.
Additionally, as a cannabinoid therapy, ZYN002’s success reflects positively on the cannabis industry.
What’s Next
Zynerba awaits confirmatory results from a pivotal clinical trial started Monday. Top-line data is due in the second half of 2019.
At time of publication, Zynerba shares were trading up 8.8 percent at $11.37 in the pre-market session.
Cannabis investors can't afford to miss the Benzinga Cannabis Capital Conference, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited—get your tickets before they sell out.
Related Links:
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
HC Wainwright Unfazed By Zynerba Ending ZYN001: Drug 'Wasn't In Our Numbers'
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
